Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied DNA Sciences, Inc. - Common Stock (NQ: APDN )

0.1825 -0.0109 (-5.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied DNA Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Sciences (NASDAQ: APDN) Receives Largest Purchase Order for LinearDNA Valued Over Mid-Six-Figures
Applied DNA Sciences, Inc. (NASDAQ: APDN) is engaged as a biotechnology company, which is focused on developing PCR-based DNA technologies. 
Via Spotlight Growth
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Launches Monkeypox Testing Service
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health
From Applied DNA Sciences, Inc.
Via Business Wire
Investors Benefit as Healthtech Comes Into Focus (VERU, APDN, TOMDF, DNA, SYBX)
Via AB Newswire
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Awarded Extension of Health Services Contract with The City University of New York
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Receives Approximately $3.6 Million in Net Proceeds from Warrant Exercise
From Applied DNA Sciences
Via Business Wire
Applied DNA to Host Conference Call and Webcast Discussing Fiscal 2022 Third Quarter Results and Corporate Updates
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Closing of Upsized $12 Million Public Offering
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Pricing of $12 Million Upsized Public Offering, Priced at a Premium to Market Under Nasdaq Rules
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Sciences (NASDAQ: APDN) Begins Validation Testing of its Monkeypox Virus PCR Diagnostic Test
Applied DNA Sciences, Inc. (NASDAQ: APDN) is a biotechnology company that is focused on producing and developing polymerase chain reaction 
Via Spotlight Growth
Topics Economy
Exposures COVID-19 Supply Chain
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website
From Applied DNA Sciences, Inc.
Via Business Wire
U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Awarded NYC-Based ‘Return-to-Office’
From Applied DNA Sciences, Inc
Via Business Wire
Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT
From Applied DNA Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.